| Waldenstrom Macroglobulinemia
Imbruvica vs Brukinsa
Side-by-side clinical, coverage, and cost comparison for waldenstrom macroglobulinemia.Deep comparison between: Imbruvica vs Brukinsa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBrukinsa has a higher rate of injection site reactions vs Imbruvica based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Brukinsa but not Imbruvica, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Imbruvica
Brukinsa
At A Glance
Oral
Once daily
BTK inhibitor
Oral
Once or twice daily
BTK inhibitor
Indications
- leukemia
- Waldenstrom Macroglobulinemia
- Graft-vs-Host Disease
- Mantle cell lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
Dosing
leukemia, Waldenstrom Macroglobulinemia 420 mg orally once daily until disease progression or unacceptable toxicity.
Graft-vs-Host Disease (age >= 12 years) 420 mg orally once daily until cGVHD progression, recurrence of underlying malignancy, or unacceptable toxicity.
Graft-vs-Host Disease (age 1 to < 12 years) 240 mg/m2 orally once daily (up to 420 mg) until cGVHD progression, recurrence of underlying malignancy, or unacceptable toxicity.
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, bruising, nausea
Serious hemorrhage, infections, cardiac arrhythmias, cardiac failure, sudden death, hypertension, cytopenias, second primary malignancies, hepatotoxicity including DILI, tumor lysis syndrome
Postmarketing hepatic failure, hepatic cirrhosis, drug-induced liver injury, interstitial lung disease, tumor lysis syndrome, anaphylactic shock, angioedema, urticaria, Stevens-Johnson Syndrome, onychoclasis, panniculitis, neutrophilic dermatoses, cutaneous vasculitis, hepatitis B reactivation, peripheral neuropathy, uveitis
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Pharmacology
Ibrutinib is a small-molecule BTK inhibitor that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK enzymatic activity and blocking B-cell antigen receptor and cytokine receptor signaling pathways necessary for B-cell trafficking, chemotaxis, and adhesion.
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Imbruvica
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
Brukinsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Imbruvica
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Brukinsa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
Humana
Imbruvica
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Brukinsa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Imbruvica.
No savings programs available for Brukinsa.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ImbruvicaView full Imbruvica profile
BrukinsaView full Brukinsa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.